Targeted Diseases

Algernon Pharmaceuticals has developed strong pre-clinical data that supports the advancement of 4 of its leading drug candidates into phase II trials in the areas of non–alcoholic steatohepatitis (NASH), chronic kidney disease (CKD), inflammatory bowel disease (IBD) and idiopathic pulmonary fibrosis (IPF).

NASH

Non–alcoholic Steatohepatitis

More about NASH

IBD

Inflammatory Bowel Disease

More about IBD

IPF

Idiopathic Pulmonary Fibrosis

More about IBD

Algernon Pharmaceuticals is a clinical stage pharmaceutical development company focused on the areas of non–alcoholic steatohepatitis (NASH), chronic kidney disease (CKD), inflammatory bowel disease (IBD) and idiopathic Pulmonary fibrosis. (IPF)

Sign up for our News Releases

Head Office

Suite 915 – 700 West Pender Street
Vancouver, BC, Canada • V6C 1G8